HEALTH● LOWAug 12 · Aug 12, 2026, 11:37 PM
Allogene outlines plan for ~100 ALPHA3 sites by year end as FDA grants RMAT and Fast Track for cema-cel
Seeking Alpha Tech
Allogene has outlined a plan to establish approximately 100 ALPHA3 sites by the end of the year, following the FDA's granting of Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track status for cema-cel. These FDA designations suggest potential for accelerated development of the therapy.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH44m agoHave a sore throat this fall? You’re not alone and a common culprit could be to blameThe Independent WorldHEALTH54m agoEbola: Africa CDC assures patient confidentiality amid contact tracingPremium TimesHEALTH1h agoConcern for Vincent Kompany: the 40-year-old Bayern Munich coach collapsed during practice and was taken to a hospitalClarínHEALTH1h agoEbola: FG orders strict screening at Nigeria’s entry pointsPremium Times